| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-02-13 | Bekinda™(extended-release formulation of ondansetron) | acute gastroenteritis | 3 | Redhill Biopharma (Israel) | Inflammatory diseases - Gastrointestinal diseases |
| 2017-02-13 | bictegravir (GS-9883) | HIV-1 Infection | 2 | Gilead Sciences (USA - CA) | Infectious diseases |
| 2017-02-13 | GS-CA1, HIV-1 capsid inhibitors | HIV-1 infection | preclinical | Gilead Sciences (USA - CA) | Infectious diseases |
| 2017-02-13 | HMPL-453 | solid tumors | 1 | Hutchison China MediTech Limited (China) | Cancer - Oncology |
| 2017-02-13 | VAL-083 - 1,2:5,6-dianhydrogalactitol | glioblastoma | 2 | DelMar Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2017-02-13 | TD-6450 and faldaprevir | hepatitis C | 2a | Trek Therapeutics (USA - MA) Theravance (Ireland) | Infectious diseases |
| 2017-02-13 | dolutegravir (Tivicay®) and rilpivirine (Edurant®) | HIV-1 infection | 3 | ViiV Healthcare (UK - USA) Janssen Pharmaceutical , a J&J company (USA - NJ) | Infectious diseases |
| 2017-02-10 | selonsertib (GS-4997) | NASH (non-alcoholic steatohepatitis) | 3 | Gilead Sciences (USA - CA) | Hepatic diseases - Liver diseases |
| 2017-02-10 | UCB7665 | myasthenia gravis | 2 | UCB (Belgium) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2017-02-10 | Ocaliva® (obeticholic acid - OCA) | NASH (non-alcoholic steatohepatitis) | 3 | Intercept Pharmaceuticals (USA - NY) | Liver diseases - Hepatic diseases |
| 2017-02-09 | cladribine | relapsing remitting multiple sclerosis (RRMS) | 3 | Merck KGaA (Germany) | Neurodegenerative diseases |
| 2017-02-08 | Opdivo® (nivolumab)+Yervoy® (ipilimumab) | non-small cell lung cancer | 1b-2 | BMS (USA - NY) | Cancer - Oncology |
| 2017-02-08 | A001 - adenovirus associated viral vector serotype 5 containing the human RPE65 gene | Leber’s Congenital Amaurosis with RPE65 mutations | 1-2 | MeiraGTx (USA - NY) | Rare diseases - Genetic diseases - Ophtalmological diseases |
| 2017-02-08 | Xarelto® (rivaroxaban) | prevention of major adverse cardiac events (MACE) including cardiovascular death, myocardial infarction and stroke in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) | 3 | Bayer Healthcare (Germany) | Cardiovascular diseases |
| 2017-02-07 | Actimab-A - Lintuzumab-Ac225 | refractory multiple myeloma | 1 | Actinium Pharmaceuticals (USA - NJ) Baylor Research Institute, | Cancer - Oncology |
| 2017-02-07 | risankizumab | psoriasis | 3 | Abbvie (USA - IL) | Autoimmune diseases - Dermatological diseases |
| 2017-02-06 | glepaglutide (ZP1848) | short bowel syndrome | 2 | Zealand Pharma (Denmark) | Rare diseases - Gastrointestinal diseases |
| 2017-02-06 | ADAIR (Abuse-Deterrent, Amphetamine Immediate-Release) | Attention Deficit Hyperactivity Disorder (ADHD) | 1 | Alcobra (Israel) | CNS diseases - Mental diseases - Neurological diseases |
| 2017-02-06 | NeuVax™ (nelipepimut-S) in combination with trastuzumab (Herceptin®) | node positive and triple negative, node negative breast cancer patients with immunohistochemistry HER2 1+/2+ expressing tumors who are disease-free after standard of care therapy | 2b | Galena Biopharma (USA - OR) | Cancer - Oncology |
| 2017-02-06 | AVXS-101 | spinal muscular atrophy (SMA) Type 1 | 1 | Avexis (USA - TX) | Rare diseases - Genetic diseases - Neuromuscular diseases |
